Volume: 5 Issue: 1
Year: 2017, Page: 68-71,
Central nervous system(CNS) demyelinative diseases are mainly Multiple Sclerosis, Acute Disseminated Encephalomyelitis (ADEM), Acute hemorrhagic Leucoencephalitis (AHL). Multiple Sclerosis is the most common. A clinically isolated syndrome is the result of a single episode of demyelination in one area of the central nervous system (a monofocal episode) or several areas of the central nervous system (a multifocal episode) which lasts for at least 24 hours. Among the people who are diagnosed with Multiple Sclerosis(MS), 85% experience an initial onset of symptoms or a first attack that is referred to as a clinically isolated syndrome (CIS). Here we are reporting different cases of central nervous system demyelinating diseases presented to Prathima Institute of Medical Sciences(PIMS) with various manifestations. Magnetic Resonance Imaging(MRI) findings have been discussed.
Keywords: Clinically Isolated Syndrome, Multiple Sclerosis, ADEM, AHL, MRI.
1. Miller D, Barkhof, Montalban, et al. Clinically isolated syndromes suggestive of multiple sclerosis, part 1: natural history, pathogenesis, diagnosis and prognosis. Lancet Neurology 2005; 4:281-288.
2. Adams and Victor’s principles of Neurology, 10th Edition, 915-937.
3. Ignacio RJ, Liliana P, Edgardo C, et al. Oligoclonal bands and MRI in clinically isolated syndromes: predicting conversion time to multiple sclerosis. Journal of Neurology 2010; 257(7):1188-91.
4. Berger T, Rubner P, Schautzer F, et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med. 2003;349:139-145.
5. Jacobs L, Beck R, Simon J, et al. Intramuscular interferon beta 1a therapy initiated during the first demyelinating event in multiple sclerosis. New England Journal of Medicine 2000; 343:898-904.
6. Comi G, Fillippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: A randomised study. Lancet 2001; 357:1576-1582.
7. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferpn beta 1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006; 67:1242-1249.
8. Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009; 374(9700):1503-11.
9. Harrison’s Principles of Internal Medicine 19th Edition;2661-2673.
Bharathkanth Reddy, Ranjith P, Israel John. Spectrum of acute central nervous system demyelinating diseases.Perspectives in medical research 2017;5(1):68-71.